NCT07099235Completed
Chart Review of Patients Undergoing Ketamine Treatments for Depression
Retrospective Chart Review of Patients Undergoing Intravenous Ketamine Treatments for Treatment-resistant Depression
Source: ClinicalTrials.gov · Last updated 1 Aug 2025
Brief summary (registry, in English)
The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression. This retrospective, observational study aims to conduct a chart review on patients receiving ketamine in a naturalistic setting to develop our understanding of ketamine as an interventional approach for treatment-resistant depression.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 250 (actual)
- First submitted
- 20 Jul 2025
- Start date
- 1 Apr 2022
- Primary completion date
- 29 Jun 2025
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Diseases
- Depression
- NCT number
- NCT07099235
What you commit to
- Study type: Observational
- Participants enrolled: 250
- From 1 Apr 2022 to the primary completion date, 29 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous ketamine use
- Previous sensitivity to ketamine or related compounds
Other illness
- History of psychosis/comorbid psychiatric disorders/psychotic depression/dissociative syndromes, significant personality disorder, as clinically assessed by psychiatrist
- History of substance misuse and/or dependence, including chronic alcohol abuse
- Acute dementia/delirium
- Unstable medical condition which may require anesthesia consult
- History of elevated intracranial pressure or cerebrovascular accident
- Recent (within 6 weeks) major cardiovascular event (such as myocardial infarction)
Other
- Using non-prescribed substance (e.g., cannabis) or alcohol use within the preceding 48 hours of treatment
- Pregnancy/breastfeeding
Who the study is looking for
- Age ≥ 18
- Able to provide informed consent
- Patient diagnosed with treatment-resistant depression
- Outpatient recommended and approved by psychiatrist for ketamine treatment
- Individuals who have previously received ECT, rTMS or any other neuromodulation can also receive ketamine
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ontario Ketamine and Infusion Centre - Toronto Site Coordinator of this site? Confirm its status | Mississauga | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.